Insights
Regulatory analysis for the people responsible for the decision
Practical explanations of how inspection evidence, company responses, quality-system performance, and remediation are evaluated together.
From Tailwind Pharma · November 4, 2026
Inside the FDA's New Inspection Playbook: 4 Surprising Shifts in How Drugs Are Approved and Monitored
FDA's updated CDER–OII Concept of Operations: remote assessments vs. inspections, MRA reliance, who makes the final classification call, and how site dossiers drive inspection priority.
Read the articleFrom Tailwind Pharma · October 29, 2026
The Great Peptide Shakeup: Key Takeaways 503A Compounders Must Know About HHS's New Policy
HHS's interim enforcement discretion for six peptides: the exact authorized salt forms, original-manufacturer COA and FEI rules, orthogonal testing, single-API and 510(k) syringe limits, and mandatory MedWatch reporting.
Read the articleFrom Tailwind Pharma · September 22, 2026
Closing a CAPA is not the same as demonstrating effectiveness
A corrective action plan can be fully executed and still leave FDA's real question unanswered. What implementation evidence, root cause, systemic scope, recurrence, and management rationale actually require.
Read the article01
FDA Inspections
What to do when an inspection is announced or already underway.
Read the guidance02
Form FDA 483 Responses
Evidence, systemic scope, commitments, and the 15-business-day response window.
Read the guidance03
Warning Letters
Why prior remediation was not persuasive and what changes at enterprise level.
Read the guidance04
Quality Systems
Investigations, CAPA effectiveness, management oversight, and sustainable control.
Read the guidance05
Data Integrity
ALCOA+, paper and hybrid records, and oversight across contract partners.
Read the guidance06
FDA Policy & Guidance
Practical interpretation through The Regulatory Mix.
Read the guidance07
Pharmaceutical Manufacturing Compliance
Inspection readiness, PAI preparation, and defensible operations.
Read the guidance08
AI in Pharmaceutical Quality
Technology-supported analysis with accountable human decisions.
Read the guidanceWeekly articles
New analysis every week on LinkedIn
Joseph publishes a weekly article on FDA enforcement trends, inspection observations, and pharmaceutical quality leadership. Read the latest on LinkedIn and follow along there.
Regulatory Mix
Where sound and AI meet CGMPs, and CGMPs meet practice.
Listen to FDA news, enforcement developments, and pharmaceutical quality topics through Tailwind Pharma’s media channel.